Compound Screening TRIZ Cases

TET proteins oxidize 5-methylcytosine into 5-hydroxymethylcytosine, enabling active DNA demethylation and more precise methylation detection.

Sequential control and treatment exposure in one live tissue sample tracks cellular activity over time while preserving the native microenvironment.

Targeted allogeneic mesenchymal stem cells reduce inflammatory cytokines and exhausted B cells while preserving protective immunity in aging frailty.

Blood-based anti-citrullinated peptide antibody measurement enables earlier aortic stenosis diagnosis and prognosis without invasive assessment.

Time-resolved fluorescence on labeled F-actin replaces slow cosedimentation, enabling faster screening of compounds that modulate actin-binding proteins.

Cell-based phenotypic assays replace costly animal models to screen neurodegenerative drug candidates with higher throughput and lower technical burden.

Quantifying phosphatase-driven dephosphorylation reveals kinase inhibitors that enhance or inhibit phosphatases, improving specificity and reducing off-target effects.

Blocking FcRn prevents IgG recycling, accelerating antibody clearance to treat autoimmune disorders without plasmapheresis risks.

Compounds that disrupt the glucagon-aP2 complex can curb abnormal hepatic glucose production and normalize blood glucose in diabetes and NAFLD.

Drug combinations that tune mitophagy can reduce mitochondrial stress and stabilize mtDNA heteroplasmy in OPA1 disease and SLSMD.

A tagged human C-peptide in recombinant cells enables rapid, low-cost insulin secretion measurement without impairing secretion.

Targeting LIX1 and YAP1 helps inhibit GIST cell proliferation, address imatinib resistance, and support prognosis prediction.

Bullvalene amino acids let cyclic peptides spontaneously interconvert into many isomers, expanding pharmacophore space for novel therapeutic discovery.

Bifunctional imide compounds separate cereblon binding from target-protein binding, improving substrate tunability for targeted ubiquitination.

SEQ ID NO: 1 and 2 peptides screen HLA-A1101-specific TCRs that activate T cells against HPV-positive tumor cells.

Linker DNA and enzyme recognition sites make recombinant nucleosome spike-ins compatible with CUT&RUN and CUT&Tag normalization.

Replacing DHFR selection with split CAT enables bacterial PPI screening in rich media, shortening growth times and simplifying assay conditions.

Small-molecule compounds provide rapid, reversible, and dosable inhibition of Cas9 and Cas12a to limit off-target editing.

Proximity-driven Michael addition between cysteine and non-canonical amino acids forms cyclic phage-displayed peptides with higher viability and target affinity.

Long-term exposure of human keratinocytes to 0.05–0.15 μM DMAIII creates a malignant transformation model for arsenic carcinogenicity and drug screening.